BioSpace News Archive

Drug Development

CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress

CatalYm announced that the mature results from its Phase 1, first-in-human trial “GDFATHER-1” will be presented in an oral presentation at the European Society for Medical Oncology Congress 2022.

September 4, 2022
·
2 min read
Drug Development

Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China

Astellas Pharma Inc. announced topline results from the Phase 3 MOONLIGHT 3™ clinical trial in women in mainland China evaluating the long-term safety and tolerability of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause.

September 4, 2022
·
7 min read
Drug Development

Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. announces that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.

September 4, 2022
·
8 min read